Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars. That’s when we’ll get the first look at data from a pivotal clinical trial of anito-cel, the personalized, BCMA-directed CAR-T therapy for multiple myeloma being developed under a partnership with Arcellx.

Anito-cel has multibillion-dollar sales potential, if it proves to be competitive on efficacy and safer from a neurotoxicity perspective than Carvykti, the currently approved BCMA CAR-T product from Johnson & Johnson and Legend Biotech. Carvykti is already on a billion-dollar run rate, with a peak sales forecast in the $5-6 billion range, according to Visible Alpha.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Beer consumption alters red blood cell lipid composition

Moderate intake of both alcoholic and non-alcoholic beer causes mild changes in red blood cell membrane lipid composition without impacting membrane fluidity.

October 22, 2024

Study explores microplastic content in urban grown lettuces

Researchers examined the level of microplastics among lettuces cultivated in urban gardens in Lisbon.

September 4, 2023

GeneDx and Prognos partner to boost treatment for rare diseases

Biopharma companies collaborating with Prognos will receive automatic alerts on clinicians diagnosing new patients. Credit: Inside Creative House / Shutterstock.com. GeneDx and Prognos Health have entered

July 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.